Teva Pharmaceuticals, recall and blood pressure
Digest more
Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining ...
The Israeli pharmaceutical company, managed by CEO Richard Francis, will publish its third quarter financial results on ...
Israel-based Phoenix Financial acquired more than 3.5 million additional shares of Teva Pharmaceuticals for an estimated $62.1 million in the third quarter. Post-transaction, the fund reported holding ...
The main Irish arm of Israeli-headquartered pharmaceutical firm Teva last year paid out dividends of $709.5 million (€617.9 ...
TipRanks on MSN
Teva launches ‘The Other TD’ disease education campaign
Pharmaceuticals announced the launch of ‘The Other TD,’ a disease education campaign leveraging the broad recognition of football ...
Investor's Business Daily on MSN
IBD Rating Upgrades: Teva Pharmaceutical ADR Flashes Improved Price Strength
A Relative Strength Rating upgrade for Teva Pharmaceutical ADR shows improving technical performance. Will it continue?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback